Evidence map›Paper›PMID 41437377›Full record

ArticleGenome biology2025

PepQueryMHC: rapid and comprehensive tumor antigen prioritization from immunopeptidomics data.

Seunghyuk Choi, Bing Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seunghyuk ChoiLester and Sue Smith Breast Center, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Bing ZhangLester and Sue Smith Breast Center, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. bing.zhang@bcm.edu.

Funding

Translating Pediatric Cancer Proteogenomic Data into Biological and Clinical InsightsU24CA271076 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Bing Zhang · 2022 to 2026
$5.0M
Cancer Prevention and Research Institute of Texas RP240137Ministry of Science and ICT, South Korea No.RS-2025-02219317NCI NIH HHS U24 CA271076
6 · The paper itself

Abstract

Determining tumor-specificity of MHC-bound peptides is crucial for cancer immunotherapy development, yet current methods struggle with class II peptides and non-reference sequences. We introduce PepQueryMHC, an ultra-fast tool that integrates MHC-bound peptide sequences with translated RNA-seq reads for efficient tumor antigen prioritization. We demonstrate its versatility in prioritizing class I and II tumor antigens, mapping the cellular origins of presented peptides, and resolving uncertainties surrounding the prevalence of proteasome-spliced peptides.

Indexed as

Antigens, NeoplasmPeptidesSoftwareHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansNeoplasmsAntigens, NeoplasmHistocompatibility Antigens Class IHistocompatibility Antigens Class IIPeptidesImmunoinformaticsImmunopeptidomeMajor histocompatibility complexProteogenomicsTumor antigens

Identifiers

PMID41437377
PMCPMC12723928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.